These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
524 related articles for article (PubMed ID: 18517081)
1. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Esch RE; Bush RK; Peden D; Lockey RF Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081 [TBL] [Abstract][Full Text] [Related]
2. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030 [TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase. Giordano T; Quarta C; Bruno ME; Falagiani P; Riva G Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):310-2. PubMed ID: 17191751 [TBL] [Abstract][Full Text] [Related]
4. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937 [TBL] [Abstract][Full Text] [Related]
5. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study. Hordijk GJ; Antvelink JB; Luwema RA Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731 [TBL] [Abstract][Full Text] [Related]
6. Sublingual immunotherapy in daily medical practice: effectiveness of different treatment schedules - IPD meta-analysis. Sieber J; Köberlein J; Mösges R Curr Med Res Opin; 2010 Apr; 26(4):925-32. PubMed ID: 20163297 [TBL] [Abstract][Full Text] [Related]
7. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808 [TBL] [Abstract][Full Text] [Related]
8. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072 [TBL] [Abstract][Full Text] [Related]
16. Advances in upper airway diseases and allergen immunotherapy. Nelson HS J Allergy Clin Immunol; 2007 Apr; 119(4):872-80. PubMed ID: 17292953 [TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Gammeri E; Arena A; D'Anneo R; La Grutta S Allergol Immunopathol (Madr); 2005; 33(4):221-3. PubMed ID: 16045861 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368 [TBL] [Abstract][Full Text] [Related]
19. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. Panzner P; Petrás M; Sýkora T; Lesná I Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908 [TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]